Table 8 Bladder
Author | Cases N | Controlsa/Cohortb | Source Population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
|---|---|---|---|---|---|---|---|---|
Castelao et al. [25] | 1,514 | 1,514a | Population based | >2 days/week for >1 month | Personal Interview | Aspirin (12%) | 0.85 | 0.66–1.09 |
|  |  |  |  |  |  | NSAIDs (39%) | 0.81 | 0.68–0.96 |
Langman et al. [36] | 1,041 | 3,122a | Population based | >7 prescriptions during months 13–36 before index date | Automated Database | NSAIDs (7%) | 1.14 | 0.85–1.53 |
Rosenberg[56] | 1,110 | 4,906a | Hospital based | >3 days/week for >3 months 1.5 years of lag time | Personal Interview | NSAIDs (6%) | 0.8 | 0.4–1.6 |
Paganini-Hill et al. [40] | 93 | 13,987b | Cohort | Daily use of aspirin for an undefined time | Mailed questionnaire | Aspirin (16%) | 1.10§ | 0.65–1.85 |
Schreinemachers et al. [43] | 35 | 12,668b | Cohort | Ever use of aspirin in the 30 days prior to start date | Personal Interview | Aspirin (59%) | 1.06 | 0.54–2.09 |
â€
-
Prevalence of exposure among controls/cohort; †Exclusive users of aspirin.